Trial Profile
A 3-month, phase III, open-label, single arm, multicenter study assessing the efficacy and safety of 0.5 mg ranibizumab monthly intravitreal injections as monotherapy in patients with visual impairment due to macular edema secondary to branch or central retinal vein occlusion (RVO)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Aug 2014 New trial record
- 07 Feb 2013
- 17 Feb 2012